.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,439,393

« Back to Dashboard

Claims for Patent: 7,439,393

Title:Phenethanolamine derivatives for treatment of respiratory diseases
Abstract: The invention relates to 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; and salts and solvates thereof, including those which are pharmaceutically acceptable, along with formulations thereof, combinations thereof, and methods for the treatment or prophylaxis of mammals by administering such compounds.
Inventor(s): Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:11/566,346
Patent Claims: 1. A compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof.

2. A compound according to claim 1 wherein said salt or solvate is pharmaceutically acceptable.

3. A compound according to claim 1, wherein the salt is selected from the group consisting of a phenylcinnamate salt, a naphthoate salt, and a mandelate salt.

4. A pharmaceutical formulation comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

5. A combination comprising a 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt or solvate thereof, and one or more other therapeutic ingredients.

6. A combination according to claim 5 wherein the one or more other therapeutic ingredients is selected from the group consisting of a PDE4 inhibitor, a corticosteroid and an anti-cholinergic agent.

7. A combination according to claim 5 wherein the one or more other therapeutic ingredients is 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarbonyl)oxy]-11.beta.-hy- droxy-16.alpha.-methyl-3-oxo-androsta-1,4-diene-17.beta.-carbothioic acid S-fluoromethyl ester.

8. A combination according to claim 5 wherein the one or more other therapeutic ingredients is 6,9-difluoro-11-hydroxy-16-methyl-17-[(4-methyl-1,3-thiazole-5-carbonyl)o- xy]-3-oxo-androsta-1,4-diene-17-carbothioic acid S-fluoromethyl ester.

9. A method for the treatment of a clinical condition in a mammal, for which a selective .beta..sub.2-adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol, or a pharmaceutically acceptable salt or solvate thereof.

10. A method according to claim 9 wherein the mammal is a human.

11. A method according to claim 10 wherein the clinical condition is asthma.

12. A method according to claim 10 wherein the clinical condition is COPD.

13. A compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol-triphenyl acetate.

14. A pharmaceutical formulation comprising a compound according to claim 13, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

15. A combination comprising a compound according to claim 13, and one or more other therapeutic ingredients.

16. A combination according to claim 15 wherein the one or more therapeutic ingredients is selected from the group consisting of a PDE4 inhibitor, a corticosteroid, and an anti-cholinergic agent.

17. A combination according to claim 15 wherein the one or more therapeutic ingredients is 6.alpha.,9.alpha.-difluoro-17.alpha.-[(2-furanylcarbonyl)oxy]-11.beta.-hy- droxy-16.alpha.-methyl-3-oxo-androsta-1,4-diene-17.beta.-carbothioic acid S-fluoromethyl ester.

18. A combination according to claim 15 wherein the one or more therapeutic ingredients is 6,9-difluoro-11-hydroxy-16-methyl-17-[(4-methyl-1,3-thiazole-5-carbonyl)o- xy]-3-oxo-androsta-1,4-diene-17-carbothioic acid S-fluoromethyl ester.

19. A method for the treatment of a clinical condition in a mammal, for which a selective .beta..sub.2-adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound according to claim 13.

20. A method according to claim 19 wherein the mammal is a human.

21. A method according to claim 20 wherein the clinical condition is asthma.

22. A method according to claim 20 wherein the clinical condition is COPD.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc